Journal: Journal of Enzyme Inhibition and Medicinal Chemistry
Article Title: Discovery of the SHP2 allosteric inhibitor 2-((3R,4R)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-(2,3-dichlorophenyl)-3-methylpyrrolo[2,1-f][1,2,4] triazin-4(3H)-one
doi: 10.1080/14756366.2022.2151594
Figure Lengend Snippet: (A) Interactions between PB17-026-01 and SHP2. (B) Interactions between PB17-036-01 and SHP2. (C) Superposition of the co-crystal structures of SHP2 in complex of SHP099 (salmon) and PB17-026-01 (yellow). Compared with SHP099, PB17-026-01 lacks the hydrogen bond with E250 but forms hydrogen bond with T253, meanwhile it is hydrogen-bonded with N ε instead of N η of R111. (D) Superposition of the co-crystal structures of SHP2 in the complex of PB17-036-01 (pink) and PB17-026-01 (yellow). The terminal group of PB17-026-01 is hydrogen-bonded with four residues T108, E110, F113, and T253, whereas the terminal group of PB17-036-01 is only hydrogen-bonded with F113 and E249.
Article Snippet: The gene sequence encoding SHP2 residues Met1-Leu525 (UniProt accession code Q06124) was synthesised by GenScript (GenScript.com) with codon optimisation for E. coli expression and inserted into pET-15b containing an N-Terminal 6 × His-tag and a tobacco etch virus (TEV) cleavage site.
Techniques: